InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,317.54
(
-0.07%
)
US TECH 100
18,242.00
(
0.05%
)
Dow Jones
39,837.24
(
-0.09%
)
Brent Oil
81.67
(
-0.95%
)
Bitcoin
69,616.82
(
-0.73%
)
Post# of 251889
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119670
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 226171

Thursday, 09/10/2020 11:13:55 AM

Thursday, September 10, 2020 11:13:55 AM

Post# of 251889
STSA—(-75%)—fails acute-migraine phase-3:

https://finance.yahoo.com/news/satsuma-pharmaceuticals-announces-topline-results-120000911.html

Topline data did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration.

The stock is now down 60% from its 2019 IPO (#msg-151112084).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up